Incanthera (AQSE:INC) Pretax Margin % : % (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Incanthera Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Incanthera's Pre-Tax Income for the six months ended in Sep. 2023 was £-0.62 Mil. Incanthera's Revenue for the six months ended in Sep. 2023 was £0.00 Mil. Therefore, Incanthera's pretax margin for the quarter that ended in Sep. 2023 was %.

The historical rank and industry rank for Incanthera's Pretax Margin % or its related term are showing as below:

AQSE:INC's Pretax Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -154.52
* Ranked among companies with meaningful Pretax Margin % only.

Incanthera Pretax Margin % Historical Data

The historical data trend for Incanthera's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incanthera Pretax Margin % Chart

Incanthera Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Pretax Margin %

Incanthera Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Pretax Margin %	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Incanthera's Pretax Margin %

For the Biotechnology subindustry, Incanthera's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Incanthera's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incanthera's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Incanthera's Pretax Margin % falls into.

Incanthera Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Incanthera's Pretax Margin for the fiscal year that ended in Mar. 2023 is calculated as

Pretax Margin	=	Pre-Tax Income (A: Mar. 2023 )	/	Revenue (A: Mar. 2023 )
	=	-1.447	/	0
	=	%

Incanthera's Pretax Margin for the quarter that ended in Sep. 2023 is calculated as

Pretax Margin	=	Pre-Tax Income (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-0.615	/	0
	=	%

Incanthera (AQSE:INC) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Incanthera Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Incanthera's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Incanthera (AQSE:INC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incanthera PLC (AQSE:INC) » Definitions » Pretax Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

76 King Street, Manchester, GBR, M2 4NH

Website

http://www.incanthera.com

Incanthera PLC is a specialist dermatology and oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It identifies and develops solutions to current clinical, commercially relevant unmet needs, utilising a new technology. The company's current products are Sol, EP0015, Equin and Duo-C. The company has one segment, namely the development of pharmaceutical products all within the United Kingdom.

Incanthera (AQSE:INC) Headlines

No Headlines